Payment overview · 2025
General Payments
$84.35
4 reported records · 3 companies
Healthcare provider profile · identity verified
Rajan Gulati, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CUBA, NY · NPI 1487735155
Verified facts
What the public records show
CMS Open Payments records show Rajan Gulati, MD received $84.35 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.83 | 42.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.72 | 40.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.80 | 17.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $84.35 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.72 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 127 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
127 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 611 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 417 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 367 | 86 |
| Lisinopril | Lisinopril | 354 | 91 |
| Furosemide | Furosemide | 353 | 78 |
| Eliquis | Apixaban | 335 | 41 |
| Gabapentin | Gabapentin | 315 | 61 |
| Losartan Potassium | Losartan Potassium | 301 | 62 |
| Sertraline Hcl | Sertraline Hcl | 292 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 49 |
| Metformin Hcl | Metformin Hcl | 248 | 56 |
| Potassium Chloride | Potassium Chloride | 207 | 39 |
| Xarelto | Rivaroxaban | 199 | 31 |
| Mirtazapine | Mirtazapine | 143 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 32 |
| Trazodone Hcl | Trazodone Hcl | 138 | 27 |
| Famotidine | Famotidine | 136 | 33 |
| Omeprazole | Omeprazole | 130 | 40 |
| Rexulti | Brexpiprazole | 127 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 19 |
| Trulicity | Dulaglutide | 106 | 21 |
| Donepezil Hcl | Donepezil Hcl | 99 | 17 |
| Meloxicam | Meloxicam | 99 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 39 |
| Alendronate Sodium | Alendronate Sodium | 94 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 27 |
| Allopurinol | Allopurinol | 86 | 20 |
| Bumetanide | Bumetanide | 85 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 35 |
| Montelukast Sodium | Montelukast Sodium | 81 | 14 |
| Carvedilol | Carvedilol | 77 | 20 |
| Alprazolam | Alprazolam | 76 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 19 |
| Finasteride | Finasteride | 65 | 12 |
| Meclizine Hcl | Meclizine Hcl | 63 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 11 |
| Simvastatin | Simvastatin | 61 | 20 |
| Jardiance | Empagliflozin | 60 | 11 |
| Tramadol Hcl | Tramadol Hcl | 60 | 16 |
| Prednisone | Prednisone | 58 | 28 |
| Scopolamine | Scopolamine | 56 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 11 |
| Ezetimibe | Ezetimibe | 52 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Risperidone | Risperidone | 48 | suppressed |
| Lorazepam | Lorazepam | 47 | suppressed |
| Glipizide | Glipizide | 45 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Azithromycin | Azithromycin | 36 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Levemir | Insulin Detemir | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 11 |
| Nystatin | Nystatin | 26 | 16 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Naproxen | Naproxen | 18 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 16 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $84.35 · 4 records | AstraZeneca Pharmaceuticals LP | FARXIGA, REXULTI, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error